Compositions and methods for treating leukemia

Patent metadata

Field	Value
Publication number	US-10676484-B2
Application number	US-201715786249-A
Country	US
Kind code	B2
Filing date	Oct 17, 2017
Priority date	May 14, 2010
Publication date	Jun 9, 2020
Grant date	Jun 9, 2020

Abstract

The invention provides compositions, methods, and kits for the treatment of acute myeloid leukemia in a subject.

First claim

What is claimed is:

1. A method for treating a leukemia in a subject, the method comprising administering to the subject an effective amount of an agent that inhibits Brd4, wherein the agent is a compound represented by the following structural formula

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the leukemia is acute myeloid leukemia (AML), Chronic Lymphocydic Leukemia (CLL), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML), Chronic Myelomonocytic Leukemia (CMML), Eosinophilic Leukemia, and Hairy Cell Leukemia.

3. The method of claim 1 , wherein the agent is a compound represented by the following structural formula:

or pharmaceutically acceptable salt thereof.

4. A method for reducing the growth, proliferation or survival of a leukemic cell, the method comprising contacting the cell with an effective amount of an agent that inhibits Brd4, thereby reducing the growth, proliferation or survival of a leukemic cell,
wherein the agent is a compound represented by the following structural formula

or a pharmaceutically acceptable salt thereof.

5. The method of claim 4 , wherein the cell is in a subject.

6. The method of claim 4 , wherein the cell is derived from an acute myeloid leukemia (AML), Chronic Lymphocydic Leukemia (CLL), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CIVIL), Chronic Myelomonocytic Leukemia (CMML), Eosinophilic Leukemia, and Hairy Cell Leukemia.

7. The method of claim 4 , wherein the agent is a compound represented by the following structural formula:

or pharmaceutically acceptable salt thereof.

8. A method of treating acute myeloid leukemia in a subject, the method comprising administering to a subject in need thereof an effective amount of an agent that inhibits Brd4, wherein the agent is a compound represented by the following structural formula

or a pharmaceutically acceptable salt thereof.

9. The method of claim 1 , wherein the subject is a mammal.

10. The method of claim 9 , wherein the subject is a human patient.

11. The method of claim 10 , wherein the human patient is an adult.

12. The method of claim 10 , wherein the human patient is a child.

13. The method of claim 8 , wherein the method reduces the growth, proliferation or survival of a leukemic cell in a subject.

14. The method of claim 8 , wherein the agent is a compound represented by the following structural formula:

or pharmaceutically acceptable salt thereof.

15. A method for treating a lymphoma in a subject, the method comprising administering to the subject an effective amount of an agent that inhibits Brd4, wherein the agent is a compound represented by the following structural formula:

or a pharmaceutically acceptable salt thereof.

16. The method of claim 15 , wherein the agent is a compound represented by the following structural formula:

or a pharmaceutically acceptable salt thereof.

17. The method of claim 15 , wherein the lymphoma is Hodgkin Lymphoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Myeloproliferative disorders or Myelodysplastic syndromes.

18. The method of claim 15 , wherein the subject is a human patient.

19. The method of claim 15 , wherein the human patient is an adult.

20. The method of claim 15 , wherein the human patient is a child.

Assignees

• Dana Farber Cancer Inst Inc
• Cold Spring Harbor Laboratory
• Cold Spring Harbor Inst

Inventors

• Bradner James Elliott
• Zuber Johannes
• Shi Junwei
• Vakoc Christopher R
• Lowe Scott W
• Mitsiades Constantine S

Classifications

• C12N2310/11

  Antisense · CPC title

• C12N2310/14

  interfering nucleic acids [NA] · CPC title

• A61K31/5517

  condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam · CPC title

• C12Q1/6886

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• C12N2330/51

  Specially adapted vectors · CPC title